Beyond ReN001 for stroke, our other cell therapy programmes are at the research or pre-clinical stages of development. Our ReN009 stem cell therapy is being developed as a treatment for peripheral arterial disease, a serious and common side-effect of diabetes. Our ReN003 programme for blindness-causing diseases of the retina is partnered with the Schepens Eye Research Institute (an affiliate of Harvard Medical School in Boston, USA). This programme is initially focused on retinitis pigmentosa, a disease leading to progressive loss of vision due to loss of the photoreceptor cells found in the retina.  

We are also exploring the clinical potential of our lead CTX stem cell line in other categories of the stroke patient population and in other neurological conditions where the mechanisms of action of the cells may be relevant.  This is with a view to commencing further clinical trials in these indications as quickly as possible, based on the very significant pre-clinical safety and efficacy data package already in existence with the CTX cells, as well as the emerging early clinical data from the PISCES stroke clinical trial, in which the CTX cells are being used clinically.

Ultimately, we expect to realise value by out-licensing our stem cell therapies to commercial development partners at the appropriate points in their respective development programmes.